124 reports of this reaction
1.3% of all MIDODRINE HYDROCHLORIDE reports
#19 most reported adverse reaction
INFUSION SITE PAIN is the #19 most commonly reported adverse reaction for MIDODRINE HYDROCHLORIDE, manufactured by Advagen Pharma Limited. There are 124 FDA adverse event reports linking MIDODRINE HYDROCHLORIDE to INFUSION SITE PAIN. This represents approximately 1.3% of all 9,858 adverse event reports for this drug.
Patients taking MIDODRINE HYDROCHLORIDE who experience infusion site pain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INFUSION SITE PAIN is a less commonly reported adverse event for MIDODRINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to infusion site pain, the following adverse reactions have been reported for MIDODRINE HYDROCHLORIDE:
The following drugs have also been linked to infusion site pain in FDA adverse event reports:
INFUSION SITE PAIN has been reported as an adverse event in 124 FDA reports for MIDODRINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INFUSION SITE PAIN accounts for approximately 1.3% of all adverse event reports for MIDODRINE HYDROCHLORIDE, making it a notable side effect.
If you experience infusion site pain while taking MIDODRINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.